Primary CNS lymphoma (PCNSL) is a potentially curable brain tumor or at least one in which durable remission can be achieved. We report follow-up study results from NABTT 96-07, a phase II multicenter trial in which 25 HIVnegative adult patients with newly diagnosed PC-NSL were treated with 8 g/m 2 of methotrexate IV every 2 weeks until a complete response (CR), as determined by radiographic criteria, was achieved or a maximum of eight induction doses was reached. 1 For patients achieving a CR, two consolidation cycles were administered every 14 days followed by 11 maintenance cycles (28 days each).
Results. We report updated results of NABTT 96-07 after a minimum of 6.5 years of follow-up. Twelve of the original 25 patients (52%) achieved a CR to methotrexate induction. Five of these 12 patients (40%) who achieved CR have not relapsed after a median follow-up of 6.8 years. Eleven patients died of progressive disease or unknown cause and 3 died from other medical illnesses (2 with cardiac disease, 1 with septic arthritis) for a total of 14 patient deaths. There were no methotrexate-related deaths. Median progression free survival was 12.8 months (95% CI: 3.5 to 37.2 months). Multiple salvage regimens, as determined by the treating physicians, were employed for relapses. Thirteen of the relapsed patients received brain irradiation (12 whole brain irradiation [WBI] and 1 radiosurgery). Nine of these 13 died. Six (24%) patients developed disease outside the CNS, 3 of whom died from systemic progression. Median diseasespecific survival has yet to be reached at 72.3 months (95% CI 37.7 months, not achieved) and median overall survival was 55.4 months (95% CI, 16.5 months, not achieved). Kaplan-Meier survival curves are displayed in the figure.
Discussion. The optimal therapeutic strategy for patients with newly diagnosed PCNSL has not been defined. Our results support the role of methotrexate as a critical chemotherapeutic agent in the treatment of PCNSL. Moreover, a subset of patients with PCNSL may achieve durable remission with methotrexate alone. In contrast, WBI alone is associated with a median overall survival of 11.6 months. 2 While it is likely that methotrexate-based combination therapy will achieve superior therapeutic results to methotrexate alone this has not been conclusively demonstrated and the optimal methotrexate-based combination regimen has yet to be defined. The toxicity of methotrexate in our study was modest with only 12 of 25 patients experiencing grade 3 or 4 toxicity after 287 cycles with no episodes of clinically relevant leukoencephalopathy. Methotrexatebased combination chemotherapy regimens are associated with higher frequencies of treatmentrelated toxicities. Regimens that contain WBI are associated with high rates of neurotoxicity in patients over the age of 60. In patients who achieve CR to methotrexate it remains to be determined what the optimal duration of therapy should be.
In another trial of methotrexate using the same dose as our study, a CR proportion of only 29.7% was achieved, less than the CR proportion of 52% observed in our study. 3 However, the maximum
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Kaplan-Meier curves for overall survival (Overall), disease specific survival (DSS), and progression free survival (PFS) for the 25 patients treated with high-dose methotrexate number of induction cycles allowed in this study was six whereas in our study the maximum number of induction cycles was eight and the median number of cycles to achieve CR was six. Thus, more than half of the CRs were achieved after receiving a seventh or eighth induction cycle in our study and it is possible that the CR proportion would have exceeded 29.7% in the other study if more induction cycles had been delivered. Further consideration of the optimal number of induction cycles is warranted. Progression-free survival in our study was shorter than that reported for some combination regimens in patients with newly diagnosed PC-NSL. 4 Moreover, the proportion of patients who experienced progression outside the CNS was higher than anticipated. However, salvage therapy was successful in many of our patients as demonstrated by the prolonged median overall survival which compares favorably to combination and WBI-containing regimens. High-dose methotrexate alone or in combination with other therapies is the most effective treatment available for PCNSL. Future studies are necessary to identify the optimal methotrexate-based combination regimen that will produce maximal efficacy and acceptable toxicity.
THE FIRST CEREBROTENDINOUS XANTHO-MATOSIS FAMILY FROM ARGENTINA: A NEW MUTATION IN CYP27A1 GENE
Cerebrotendinous xanthomatosis (CTX) is a treatable, autosomal recessive, lipid storage disorder characterized by diarrhea and cataracts, usually appearing in the first decade of life, followed by growth of tendon xanthomas and progressive neurologic disability. 1 The typical brain findings include MRI signal abnormalities mainly in the globus pallidus and dentate nuclei. 2 The disease is caused by deficiency of the mitochondrial enzyme, sterol 27-hydroxylase, resulting in impaired primary bile acid synthesis, decreased chenodeoxycholic acid production, and cholestanol accumulation in virtually every tissue. 3 The main blood chemistry abnormalities include high plasma levels of cholestanol with normal to low cholesterol. Different mutations of the CYP27A1 gene have been described. 4 Early diagnosis is crucial as treatment with chenodeoxycholic acid (CDCA) may improve symptoms. 5 Here we report the cases of two Argentinian siblings with a novel mutation of the CYP27A1 gene associated with clinical variants, including absence of tendon xanthomas. 1 (male, 17 years) . The first clinical manifestation was chronic diarrhea from birth and growth retardation. Episodes of febrile seizures occurred at 1 and 3 years, followed by photosensitive epileptic syndrome. Posterior subcapsular cataracts were found at 3 years and removed at 8 years of age. Mild mental retardation, attention deficit, and hyperactivity were reported at school age. At 17 years of age physical examination showed low height and weight, brownish dental enamel, long upper extremities, scoliosis, and lumbar hyperlordosis. Neurologic examination showed palatal myoclonus, dystonic posture, distal tremor, and uncoordinated gait. Tendon reflexes were diffusely hyperactive. No tendon xanthomas were found. EEG showed abnormal response to photostimulation. T2-W MRI revealed a very small hyperintense area near the 2 (female, 14 years) . The patient had chronic diarrhea since the first month of life, followed by developmental delay, photosensitive epilepsy, and bilateral cataracts, removed at 8 years of age. Mild mental retardation was evident at school age. At 14 years, clinical examination revealed growth retardation, brownish dental enamel, and distal tremor. No tendon xanthomas were found. EEG showed abnormal photostimulation response. MRI was normal.
Case reports. Case
Both patients had high plasma levels of cholestanol (33.4 and 21.1 mol/L; normal value 3.3 to 12.5 mol/L), associated with increased 27-norcholestanepentol and cholestanepentol levels in the urinary bile acid profile. Treatment with 750 mg/day CDCA was followed by progressive improvement of diarrhea and significant improvement of neurologic disability.
Analysis of CYP27A1 gene. After obtaining informed consent, genomic DNA was extracted from blood samples of the two patients with CTX, a sibling, and their parents. Exons 1 through 8 and the promoter region of CYP27A1 were amplified by PCR using suitable oligonucleotide primers. Sequencing of exon 1 revealed the novel 11_12insTGGGCTGCGC mutation in one allele (figure, A), while exon 6 showed the mutation R395C in the second allele (figure, B) of the two affected siblings.
Discussion. CTX is a rare familial neurometabolic disorder, more common among Jews of Moroccan origin. The largest patient series have been reported in the Netherlands, Italy, and Israel; however, single cases have been described all over the world. The cases reported here are the first in Argentina. The diagnosis of CTX was confirmed by molecular study of the CYP27A1 gene, 4, 6 which showed a novel mutation, a 10 bp insertion, in exon 1. The second mutation was an R395C substitution, already described in patients from different countries.
The clinical phenotype of our patients shows some noteworthy features: absence of tendon xanthomas, predominant extrapyramidal manifestations and palatal myoclonus, and very minimal MRI findings.
Tendon xanthomas are one of the clinical hallmarks of CTX, usually presenting in the second or third decade of life, in most cases before neurologic symptoms. The absence of tendon xanthomas has only been reported occasionally and may be clinically misleading. 6 Though xanthomas may manifest at a later date in these two young patients, a phenotypic variant due to specific CYP27A1 gene mutations cannot be ruled out.
Besides mild mental retardation and behavioral changes, the predominantly extrapyramidal manifestations, with dystonia and hand tremor, are noteworthy. Moreover, one patient has palatal myoclonus, which was first reported by van Bogaert et al. 7 in the original description of CTX, but has rarely been found since then.
In conclusion, this report suggests that it is mandatory to consider the possibility of CTX in young patients with mental retardation, persistent diarrhea since infancy, and early-onset cataract, even in the absence of tendon xanthomas and MRI evidence of very mild cerebellar abnormalities. Early diagnosis is crucial because treatment with chenodeoxycholic acid reverses metabolic abnormalities and prevents or improves neurologic dysfunction, as in the present cases. 
